Solving the Specialty Medication Adherence Problem in the GLP-1 Market

GLP-1s have been big news and in high demand. What started as a breakthrough treatment for type 2 diabetes has triggered a major shift in metabolic care with potential for even more indications.

But strong prescribing volume doesn’t tell the full story. Many patients never fill the script, or they discontinue the medication within months, preventing them from realizing the full benefits of GLP-1 therapy.

For pharma teams, the takeaway is clear: Long-term market success will not come from new-to-brand starts alone. The infrastructure supporting specialty medication access and adherence needs to be strengthened.

Why do patients stop taking GLP-1 medications for weight loss?

Early discontinuation of GLP-1 therapies is often driven by prior authorization (PA) barriers, out-of-pocket costs, and side effects. While titration makes GLP-1s easier to tolerate, patients may drop off therapy if the pace of their results doesn’t match their expectations. To better manage these friction points, pharmaceutical brands need to reach prescribers and patients at critical moments between prescribing and persistence.

What Real-World Data Tells Us About the GLP-1 Adherence Cliff

Numerous GLP-1 clinical trials for weight loss have seen adherence at the one-year mark exceeding 80%, according to a study published in the Journal of Managed Care & Specialty Pharmacy. However, when these specialty therapies enter the real world, the illusion of persistence falls away. The study found that among 4,066 people on GLP-1 therapy to treat obesity:

• 27% took their medication as prescribed
• 33% stayed on treatment beyond a year

It’s important to note that the study took place when GLP-1 shortages were at their peak. But side effects likely influenced low persistence rates, too. Even now, with supply chain issues largely resolved, 39% of patients prescribed a GLP-1 for weight loss drop off within one year.

As a result, health plans and self-insured employers are putting real-world evidence under the microscope. When most patients stop therapy within the first 12 months, payers may not see the long-term value of these medications, such as fewer cardiovascular events or improving health outcomes.

This can lead to tighter formulary rules and more utilization management. Nearly three-quarters (72%) of PBMs/payers reported that discontinuation rates and weight regain had at least a moderate impact on their GLP-1 coverage decisions, according to the Pharmaceutical Strategies Group (PSG) 2026 Trends in Drug Benefit Design Report.

3 Structural Failure Points Impeding Adherence to GLP-1 Therapies

1. The Clinical Titration Phase

Gastrointestinal side effects (nausea, vomiting, diarrhea) hit hardest during the first 16 to 24 weeks as patients step up their dosages. The clinical reality of this issue was starkly highlighted in phase 3 clinical trial data for an investigational dual GLP-1/glucagon receptor agonist. The trial showed remarkable metabolic efficiency, including a massive 63% reduction in liver fat, as reported by the American Journal of Managed Care.

Yet, even in this highly structured clinical trial setting, up to 20% of participants stopped treatment due to side effects during the dose-escalation phase. In the real world, without a clinical trial coordinator actively managing a patient’s expectations, treatment abandonment happens faster, with little visibility into the reasons.

2. The Re-Authorization Hurdle: A 6-Month Administrative Wall

Payers rarely grant open-ended coverage for weight management or advanced metabolic indications. Many commercial formularies mandate a renewal of the PA at four- or six-month intervals, including documented medical evidence to show that the patient has achieved a positive clinical benefit. This can disrupt patients’ clinical momentum and trigger abandonment or therapy switching.

3. The Capacity Failure: Hub Services Not Built for Mass Volumes

Many traditional specialty therapy hubs are designed for low-volume, high-touch rare disease or oncology medications. They rely heavily on manual intervention—paperwork, faxes, and phone calls. A flood of new patients could contribute to backlogs that make drop-off rates rise even further.

Upcoming Pressure Test on Clinical Workflows and Patient Support Programs

On July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program, a temporary demonstration program that runs through December 2027.

The program operates outside standard Part D benefit payment flows, allowing eligible Medicare beneficiaries with a body mass index (BMI) greater than or equal to 35 (or greater than or equal to 27 with specific comorbidities like uncontrolled hypertension or pre-diabetes) to access select weight-management GLP-1 formulations for a flat, predictable copay of $50 per month.

While the program appears to be a market access win, it introduces operational bottlenecks:

• No Part D Automation: Because the Bridge operates entirely outside the standard Part D architecture, traditional automated pharmacy benefit verifications will fail.

• Manual Central Processor Gateway: All claims, eligibility verifications, and clinical PAs must be routed directly through a single, centralized processor.

• Potential for Immediate Attrition: Millions of previously excluded older adults are about to flood the system. Point-of-care PA friction may skyrocket, which could trigger a wave of first-fill rejections and create an immediate adherence cliff before the first dose is dispensed.

In addition, since only three drugs are covered, it’s likely to increase therapy switching for patients.

How to Help Improve Specialty Medication Access and Adherence

To protect brand value, support formulary access, and meet growing demand, pharma teams need to invest in programs that help patients start and stay on therapy.

Integrate Actionable Prescribing Support in the EHR Workflow

Overextended providers don’t need more friction. Prescription rework, complex PAs, and pharmacy routing issues take time away from patient care. Brands can help reduce those frustrations once a treatment is selected by connecting the provider to:

• Information about new or expanded indications, efficacy studies, or prescribing guidelines, lowering the cognitive burden on clinicians.
• Therapy-specific dosing information, standardized regimen instructions, and limited distribution network needs, so prescriptions arrive at the pharmacy ready to fill.
• Targeted questions, based on real-time clinical and patient benefits data, to help ensure PA requests meet payer requirements, reducing rework and speeding time-to-therapy.

Support Patients From First Fill, Dose Titration, and Beyond

Brands can invest in digital programs that support patients at key moments in their therapy journey. For example, provider-to-patient text messages sent shortly after a patient leaves the doctor’s office can connect them to medication-specific information, copay cards or other financial support, or a nurse navigator who can help with therapy initiation and tolerability concerns.

Use Real-World Adherence Data to Show Value

As payers look for long-term value, brands should collect and share real-world data on adherence and persistence. Showing that patients stay on therapy beyond the first year can help strengthen the case for formulary access and ongoing coverage.

What’s Your Next Move?

The first era of the GLP-1 market was a sprint for market share. The next will be a marathon focused on keeping patients on therapy. Initial prescription volume will still matter, but long-term success will depend on what happens after the prescription is written. Brands that build a smoother, more connected support system can help reduce friction, address adherence challenges, and keep patients moving forward in their treatment journey.

Ready for a deeper dive into this topic? Read our white paper, “Cutting Through the Noise: The Breakdown Between GLP-1 Prescribing and Patient Persistence,” for a more in-depth look at the challenges ahead.